At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 62 enrolled
Drug / intervention
Ocriplasmin 0.125 mg in a 0.1 mL volumedrug
Likely dose
Ocriplasmin 0.125 mg in a 0.1 mL volumefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Anatomical and Functional Outcomes in Subjects Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)
In Brief
A Phase 4 clinical trial evaluating Ocriplasmin 0.125 mg in a 0.1 mL volume for Vitreomacular Traction and Vitreomacular Adhesion. Completed, enrolled 62 participants across 1 site.
Detailed Summary
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitreomacular Traction, Vitreomacular Adhesion
CountriesAustralia
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartMay 2015
Primary CompletionDec 2015
Study CompletionMay 2016
TodayJul 2026
First PostedDec 23, 2014
Enrollment StartMay 26, 2015
Primary CompletionDec 11, 2015
Study CompletionMay 9, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.5 years ago
Interventions
Ocriplasmin 0.125 mg in a 0.1 mL volumedrug